ADC Therapeutics Reports Impressive Results and Financial Updates for Q2 2025 ADC Therapeutics has released its Q2 2025 financial results, showcasing significant operational advancements and strong clinical data for its product ZYNLONTA®.

ADC Therapeutics Reports Impressive Results and Financial Updates for Q2 2025 #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #glofitamab

Eddie Cliff: COALITION Study Compares Results of Glofitamab Combinations in LBCL - OncoDaily Eddie Cliff: COALITION Study Compares Results of Glofitamab Combinations in LBCL / Adrian Minson, cancer, Chan Y. Cheah, Eddie Cliff, Emma Verner, Jason

COALITION Study Compares Results of Glofitamab Combinations in LBCL - Eddie Cliff
@eddiecliff.bsky.social

oncodaily.com/science/coal...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #COALITION #Lymphoma #LBCL #Glofitamab

ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL In an 8 to 1 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 STARGLO trial are not applicable to patients in the US with diffuse large B-cell lymphoma.

📍 L’ #ODAC de la #FDA a voté à 8 contre 1 contre l’applicabilité des résultats de l’essai #STARGLO pour les patients atteints de DLBCL R/R

Cette décision a un impact sur l’utilisation du #Glofitamab ( #Columvi) avec #GemOx pour le traitement du #Lymphome #DLBCL

www.targetedonc.com/view/odac-vo...

ADC Therapeutics to Share Preliminary Data from LOTIS-7 Clinical Trial on December 11, 2024 On December 11, 2024, ADC Therapeutics will host a live conference call to discuss initial findings from the LOTIS-7 clinical trial, focusing on advanced lymphoma treatments.

ADC Therapeutics to Share Preliminary Data from LOTIS-7 Clinical Trial on December 11, 2024 #Switzerland #ADC_Therapeutics #ZYNLONTA #Lausanne #glofitamab